| __timestamp | Alpine Immune Sciences, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 302156000 |
| Thursday, January 1, 2015 | 6844000 | 402271000 |
| Friday, January 1, 2016 | 8586000 | 476593000 |
| Sunday, January 1, 2017 | 6079000 | 554336000 |
| Monday, January 1, 2018 | 8362000 | 604353000 |
| Tuesday, January 1, 2019 | 9467000 | 680924000 |
| Wednesday, January 1, 2020 | 10899000 | 737669000 |
| Friday, January 1, 2021 | 14560000 | 759375000 |
| Saturday, January 1, 2022 | 17968000 | 854009000 |
| Sunday, January 1, 2023 | 22222000 | 937300000 |
| Monday, January 1, 2024 | 1009025000 |
Unleashing the power of data
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc. over the past decade. BioMarin, a leader in the industry, has consistently maintained higher SG&A expenses, peaking at approximately $937 million in 2023. This reflects their expansive operations and robust market presence. In contrast, Alpine Immune Sciences, a smaller player, has shown a steady increase in SG&A expenses, reaching around $22 million in 2023, a tenfold increase since 2014. This growth indicates Alpine's strategic investments in scaling operations. The data highlights the contrasting scales and strategies of these companies, offering insights into their operational priorities and market strategies. As the biotech landscape evolves, understanding these financial dynamics is crucial for investors and industry stakeholders.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Comparing SG&A Expenses: Alkermes plc vs Alpine Immune Sciences, Inc. Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights